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Background: During the past years biologic agents (also termed biologicals or biologics)
have become a crucial treatment option in immunological diseases. Numerous articles
have been published on biologicals, which complicates the decision making process
on the use of the most appropriate biologic for a given immune-mediated disease. This
systematic review is the first of a series of articles assessing the safety and efficacy of B
cell-targeting biologics for the treatment of immune-mediated diseases.
Objective: To evaluate rituximab’s safety and efficacy for the treatment of
immune-mediated disorders compared to placebo, conventional treatment, or
other biologics.
Methods: The PRISMA checklist guided the reporting of the data. We searched
the PubMed database between 4 October 2016 and 26 July 2018 concentrating on
immune-mediated disorders.
Results: The literature search identified 19,665 articles. After screening titles and
abstracts against the inclusion and exclusion criteria and assessing full texts, 105 articles
were finally included in a narrative synthesis.
Conclusions: Rituximab is both safe and effective for the treatment of acquired
angioedema with C1-inhibitor deficiency, ANCA-associated vasculitis, autoimmune
hemolytic anemia, Behçet’s disease, bullous pemphigoid, Castleman’s disease,
cryoglobulinemia, Goodpasture’s disease, IgG4-related disease, immune
thrombocytopenia, juvenile idiopathic arthritis, relapsing-remitting multiple sclerosis,
myasthenia gravis, nephrotic syndrome, neuromyelitis optica, pemphigus, rheumatoid
arthritis, spondyloarthropathy, and systemic sclerosis. Conversely, rituximab failed
to show an effect for antiphospholipid syndrome, autoimmune hepatitis, IgA
nephropathy, inflammatory myositis, primary-progressive multiple sclerosis, systemic
lupus erythematosus, and ulcerative colitis. Finally, mixed results were reported for
membranous nephropathy, primary Sjögren’s syndrome and Graves’ disease, therefore
warranting better quality trials with larger patient numbers.
Keywords: rituximab, CD20, B cell, monoclonal antibody, immune-mediated disease, autoimmune disease,
inflammatory disease
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INTRODUCTION
Most immune-mediated disorders are thought to arise due to
a deficiency in immune tolerance or an imbalance of immune
activation and immune tolerance. Previously, treatment options
included corticosteroids and immunosuppressive drugs, which
also affect protective immunity and often lead to serious side
effects. Since their emergence for the treatment of immunological
diseases, the number of biological agents (also termed biologicals
or biologics) has grown rapidly and numerous studies assessing
their properties have been published. Consequently, to have an
overview on the safety, efficacy, and impact biologicals have
on quality of life (QoL) is difficult. Therefore, this systematic
review is the first of a series of articles focusing on the safety
and efficacy of B cell-targeting biologics for the treatment
of immune-mediated diseases. The series will concentrate on
molecules targeting either B cell-activating factor (BAFF; also
known as TNF ligand superfamily member 13B or B lymphocyte
stimulator) or CD20. BAFF is produced by myeloid cells and
radiation-resistant stromal cells in lymphoid follicles as well as
the bone marrow. It plays a major role in the survival and
maturation of follicular B cells. The function of the surface
molecule CD20 is not quite clear yet. However, monoclonal
antibodies directed against CD20 or BAFF affect the B cell
population and, therefore, induce a decrease in the production
of antibodies.
The aim of this systematic review is to provide an overview
on the (i) efficacy and (ii) safety of the anti-human CD20
monoclonal antibody rituximab (RTX) compared to placebo,
conventional treatment or other biologics in patients suffering
from immune-mediated disorders.
METHODS
Study Design and Protocol Registration
The PRISMA checklist guided the reporting of this systematic
review (Table 1) (1). Our protocol was registered with
PROSPERO number CRD42018104726. During the course
of our research we found that a considerable number of case
series did not state whether they were conducted prospectively
or retrospectively. We thus amended this subpoint of our search
strategy and included case series with at least three patients when
Abbreviations: ACR, American College of Rheumatology; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; AZA, azathioprine; CAS,
clinical activity score; CYC, cyclophosphamide; C1-INH-AAE, acquired
angioedema with C1-inhibitor deficiency; DAS, disease activity score;
DLCO, diffusing capacity of the lungs for carbon monoxide; DMARD,
disease-modifying antirheumatic drug; eGFR, estimated glomerular filtration
rate; EMA, European Medicines Agency; EULAR, European League Against
Rheumatism; FDA, United States Food and Drug Administration; HAQ, health
assessment questionnaire; HIV, human immunodeficiency virus; ITP, immune
thrombocytopenia; MS, multiple sclerosis; MTX, methotrexate; NIAT, non-
immunosuppressive antiproteinuric treatment; Peg-IFN-α, pegylated interferon
α; PGA, patient global assessment; PPMS, primary progressive MS; QoL, quality
of life; RA, rheumatoid arthritis; RCT, randomized controlled trial; R-CVP,
RTX, CYC, vincristine and prednisone; RRMS, relapsing-remitting MS; RTX,
rituximab; SAE, serious adverse event; SF-36, 36-item short form health survey;
TADAI, total adjusted disease activity index; VAS-F, visual analog scale to evaluate
fatigue severity.
the study design was prospective or unknown, whereas studies
stating they were retrospective were excluded.
Search Strategy
We searched the PubMed database between 4 October 2016
and 26 July 2018. Our full search strategy and research terms
were defined in advance (see Table S1). If publications were
not available via open or institutional access, study authors
were contacted.
Eligibility Criteria
We included randomized controlled trials (RCTs), their
extension trials and their substudies with predefined endpoints.
If there were no RCTs, we included prospective case series
including at least three patients and non-randomized clinical
studies with at least five patients per intervention group. We
excluded retrospective trials, post hoc-analyses, meta-analyses,
reviews, studies made from registries and studies carried out on
animal models or where the primary endpoint was non-clinical.
Studies had to be available in English or German.
Study Selection, Data Collection Process,
and Analysis
Three authors (CK, BW, and OB) developed and tested a data
extraction sheet, whereupon five authors independently (CK,
BW, US, AV, and AM) searched PubMed according to the
predefined search terms, checked titles and abstracts, carried
out a full-text review of the selected studies, and extracted the
relevant data. Any disagreements about study inclusion were
resolved by consensus.
Risk of Bias Assessment
CK, JS, and CC used a modified version of the Downs and Black
tool (see Table S2) to undertake a quality assessment including a
risk of bias of the studies recovered (2). The studies were scored
out of a maximum of 28 points for the following categories: (i)
reporting, (ii) external validity, (iii) internal validity, and (iv)
power, and the scores were summed and ranked high, medium
and low quality. Any discrepancies were resolved by consensus.
As we limited our research strategy to the PubMed database,
the reference list of these studies, and the expertise of the authors
involved, we did not conduct a risk of bias assessment across the
studies, as we believed the risk of publication bias would have
been high.
Principal Summary Measures and
Synthesis of Results
Our aim was to assess the efficacy and safety of RTX as well as its
influence on QoL when used in different immunologic diseases.
Since we wanted to give an overview including also rare diseases
we did not specify in more detail these endpoints in order not to
exclude potentially important studies.
RESULTS
Study Selection and Characteristics
A total of 19,665 articles were identified on PubMed. After
screening titles, abstracts and full texts, 105 articles were included
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TABLE 1 | The preferred reporting of systematic reviews and meta-analysis (PRISMA) checklist.
Section/topic # Checklist item Reported on
page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both 1
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions
and implications of key findings; systematic review registration number
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known 2
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS)
2
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number
2
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale
2
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched
2
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated
2
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis)
2
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made
2
Risk of bias in individual
studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this
was done at the study or outcome level), and how this information is to be used in any data synthesis
2
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means) 2
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis
2
Risk of bias across
studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective
reporting within studies)
2
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done,
indicating which were pre-specified
NA
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions
at each stage, ideally with a flow diagram
2, Figure 1
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period)
and provide the citations
2, Table S3
Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12) 12, Table 2
Results of individual
studies
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot
4–12
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency NA
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item 15) 11–12
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]) NA
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance
to key groups (e.g., healthcare providers, users, and policy makers)
12
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias)
13
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future
research
13
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for
the systematic review.
15
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in our study (Figure 1). Study characteristics are available
in Table S3.
Synthesized Findings
The following text highlights themost important findings of what
is currently known.
Acquired Angioedema With C1-Inhibitor Deficiency
(C1-INH-AAE)
We found two case series including three patients each,
suffering from C1-INH-AAE (3, 4). In both studies, the
angioedema attacks were markedly reduced with the use of RTX.
Furthermore, most of the patients showed a normalization of C1-
inhibitor levels. Health-related QoL was not analyzed. One study
did not report any safety events (3). The other study, reported
one patient experiencing an adverse event (AE) with no serious
adverse event (SAE) (4).
Discussion
Available data is derived from unblinded case series of a total
of six patients. Further trials with a randomized-controlled
design including more patients are needed to verify the available
promising results.
FIGURE 1 | PRISMA diagram of the literature search.
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ANCA-Associated Vasculitis
Of nine trials included, five were randomized and only one
of them was double-blind (5–13). The other four trials were
either extension trials or substudies. Five hundred and thirty
five patients participated in the five original trials, suffering
from either granulomatosis with polyangiitis or microscopic
polyangiitis. RTX was either used as a maintenance or induction
therapy. Its efficacy and safety were compared to azathioprine
(AZA), cyclophosphamide (CYC), infliximab, or RTX at a
different dosing regimen. All studies allowed concomitant use of
corticosteroids. Durations of the different studies ranged from 6
to 28 months and primary endpoints were quite varied.
In the RAVE trial (6) patients were treated with either RTX
in combination with CYC or CYC alone. Patients in the CYC
group were allowed to switch to AZA. The study failed to
reach its primary endpoint, remission of disease with successful
prednisone taper by month 6. For all endpoints, RTX treatment
was comparable with CYC and AZA. The results remained
insignificant during the extension trial (7). However, an open-
label extension of this trial showed convincing remission rates
after retreatment with RTX and prednisone (8).
The RITUXVAS trial (9) investigated sustained remission
as primary endpoint and found no difference between RTX
in combination with CYC and CYC alone. Additionally, its
extension trial failed to show superiority of RTX when analyzing
the composite outcome of death, end-stage renal disease or
relapse as primary endpoint (10).
De Menthon et al. (11) compared the efficacy of RTX with
infliximab and found numerically but not significantly better
results in RTX-treated patients.
The only trial with significant results was the MAINRITSAN
study (12), which investigated the use of RTX as maintenance
therapy in comparison to AZA. There was a significant reduction
in major relapses at month 28, whereas the difference in
minor relapses was comparable. The MAINRITSAN2 (13) trial
compared a fixed vs. a variable RTX dosing regimen and found
no differences concerning the number of relapses at 28 months.
As for safety, studies providing data about AEs showed
comparable rates of incidence between RTX and the
control groups.
Both the RAVE and the RITUXVAS trial assessed the change
in QoL using the 36-item short form health survey (SF-36) score,
but did not find any significant improvements (6, 9).
Discussion
Since safety assessments were convincing and efficacy
measurements were comparable with standard of care treatment,
RTX was approved by the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) for the treatment of
granulomatosis with polyangiitis and microscopic polyangiitis.
Antiphospholipid Syndrome
Only one uncontrolled prospective, open-label trial conducted
over a period of 12 months testing efficacy and safety of
RTX in 19 patients with antiphospholipid syndrome met our
inclusion criteria (14). Patients with a diagnosis of systemic
lupus erythematosus (SLE) or systemic autoimmune disease
were excluded. Regular therapeutic medication for this disease
was allowed.
Assessment of thrombocytopenia, cardiac valve disease, skin
ulcers, antiphospholipid nephropathy, and cognitive dysfunction
did not reveal a substantial therapeutic effect. Forty nine AEs and
12 SAEs were reported during the 12 month study period. With
regard to QoL, there were no significant changes in the SF-36 and
patient global assessment (PGA) score at 24 weeks.
Discussion
Available data is limited to one uncontrolled prospective, open-
label trial and the results of this study in 19 patients did not show
any significant therapeutic effect.
Autoimmune Hemolytic Anemia
Two RCTs, one double-blind and the other open-label,
comprising 96 patients were included in our analysis (15, 16).
Only patients with a warm autoimmune hemolytic anemia with
a positive direct antiglobulin test were included. Study duration
was 1 and 2 years, respectively.
Both trials showed significantly higher response rates in
patients receiving additional RTX after 12 months of treatment
compared to corticosteroid treatment alone and did not report
any significant differences concerning blood cell transfusion,
splenectomy, hospitalizations, and corticosteroid dose. While the
RAIHA trial (16) provided no information on AEs, Birgens et al.
(15) reported no significant difference in the occurrence of AEs
between both arms of their study. Neither study analyzed QoL.
Discussion
Available studies were conducted as RCTs and showed a marked
superiority of RTX in combination with corticosteroids as
compared to corticosteroids alone. However, RTXwas only tested
in 96 patients and further studies conducted in larger groups of
patients are needed to confirm these initial findings.
Autoimmune Hepatitis
Only one open-label trial assessing six patients conducted over a
72 week period met our inclusion criteria (17). The diagnosis of
autoimmune hepatitis had to be proven by biopsy. All included
patients had an inadequate repsonse to prednisone and/or AZA.
The primary endpoint was safety with only two patients
experiencing AEs, none of them considered serious. After
24 weeks there was a significant change in aspartate
aminotransferase (AST) (p = 0.032), but not alanine
aminotransferase (ALT) (p = 0.068), bilirubin, gammaglobulin,
and IgG levels. There was no significant change in the nine-point
fatigue severity scale.
Discussion
Only one unblinded trial without a clinical endpoint matched
our inclusion criteria. Further studies are needed to make a
suggestion about the efficacy of RTX in autoimmune hepatitis.
Behçet’s Disease
One randomized-controlled investigator-blinded study analyzing
the total adjusted disease activity index (TADAI) as primary
endpoint was included (18). The 20 patients had refractory
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disease with long-standing ocular involvement. The control
group received AZA, CYC, and corticosteroid treatment,
whereas the RTX group was also given methotrexate (MTX)
and prednisolone.
The study showed a significant improvement in TADAI (p =
0.009), posterior uveitis and ocular edema, which was however
not superior to the comparator (p= 0.2). Seven patients from the
RTX group reported at least one AE, compared to one AE in the
comparator group. QoL was not assessed.
Discussion
Provided information is scant and further studies are necessary
to analyze RTX in patients with Behçet’s disease.
Bullous Pemphigoid
Hall et al. published a case series comprising seven patients with
bullous pemphigoid conducted over a period of 12 months (19).
Patients had persistent disease despite the use of prednisone.
Disease activity was significantly improved with no new skin
lesions appearing. This correlated with a significant decrease in
anti-BP180 antibody levels. There were no SAEs reported and
there was no information about the frequency of AEs.
Discussion
Although there is only one case series available, the results are
promising. However, RCTs including a sufficient number of
patients are needed to prove those findings.
Castleman’s Disease
We found eight trials eligible for inclusion (20–27). Studies were
either case series or open-label trials without a control group. In
total 81 patients suffering from multicentric Castleman’s disease
were treated with RTX. Diagnosis had to be proven by biopsy and
patients had to have associated human immunodeficiency virus
(HIV) infection, except in one trial (23).
The only trial with a predefined primary endpoint stated
that 92% of the patients achieved sustained remission off
chemotherapy (22). A great proportion of patients in the other
studies also achieved remission. Four trials reported a positive
influence on the Kaposi sarcoma-associated herpes virus viral
load (21, 24, 26, 27). Although reporting of AEs was incomplete,
aggravation of Kaposi sarcoma was a point of concern.
Discussion
There are only case series and one open-label study available,
however, available results seemed promising. Reactivation of
Kaposi sarcoma was an important AE.
Cryoglobulinemia
Three unblinded RCTs and one follow-up study met our
inclusion criteria totaling 118 patients (28–31). Except for four
patients from the study of De Vita et al. (29), all patients were
hepatitis C virus positive. Patients with hepatitis B virus or
HIV positivity were excluded. Treatment in the control groups
varied markedly.
The primary endpoint was met in all three RCTs. Dammacco
et al. (28) reported that more patients receiving a combination
therapy of pegylated interferon α (Peg-IFN-α) weekly plus
ribavirin daily in combination with RTX 375 mg/m2 weekly for 4
weeks reached complete response as compared to Peg-IFN-α and
ribavirin alone (p < 0.05) (28). Following RTX 1,000mg on days
0 and 14, De Vita et al. reported a significant reduction in global
disease activity as measured by the Birmingham vasculitis activity
score after 2 months with sustained response until month 24 and
a median duration of clinical response of 18 months (29). Sneller
et al. (30) stated a significantly higher remission rate in patients
receiving RTX.
Information about AEs was sparse among the studies making
an interpretation of safety difficult. QoL was not assessed.
Discussion
Available information about the efficacy of RTX in patients with
cryoglobulinemia is promising.
Goodpasture’s Disease
Only one case series including three patients matched our
inclusion criteria (32). Patients were followed between 33 and
49 months.
In all three patients, anti-glomerular basement membrane
antibodies were no longer detectable. Patients two and three
were able to discontinue corticosteroid treatment, while
patient one remained dialysis dependent. There were no
complications reported.
Discussion
Since the only available study included three patients, it is not
possible to state whether RTX could be a future treatment option
in Goodpasture’s disease.
Graves’ Disease
Two double-blind RCTs with 56 patients with euthyroid
function suffering from Graves’ orbitopathy were identified for
inclusion (33, 34). The control groups received either placebo
or methylprednisolone.
The study of Salvi et al. (33) found a significant improvement
of the clinical activity score between baseline and week 24 and
a significant improvement in eye motility. Contrarily, Stan et al.
(34) could not report any significant improvement. AEs occurred
more often in patients treated with RTX.
Discussion
Currently only two RCTs have investigated the use of RTX
reporting of contradictory results. Further trials with more
patients are needed to clarify the role of RTX in Graves’ disease.
IgA Nephropathy
Lafayette et al. conducted an open-label RCT with 34 patients
suffering from IgA nephropathy and concomitant proteinuria
(35). Authors observed no difference between the treatment arms
concerning proteinuria or estimated glomerular filtration rate
(eGFR), which were the primary endpoints. They reported mild
AEs in the RTX group but no SAEs.
Discussion
The only available trial found no significant difference between
RTX and standard-of-care treatment.
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IgG4-Related Disease
Five non-randomized trials comprising 52 patients were
included. None of the trials included a control group and four
were stated as case series. Follow-up ranged from 4 to 48 months.
In the three studies investigating RTX as an induction
treatment, RTX led to reduction of IgG4 serum levels and
enabled patients to reduce or even discontinue corticosteroids
(36–39). Furthermore, Yamamoto et al. (39) reported similar
findings when RTX was used in disease relapses. In patients with
IgG4-related kidney disease, RTX led to improvement in eGFR
and reduction in inflammatory retroperitoneal fibrous tissue in
patients with retroperitoneal fibrosis (40).
The incidence of AEs and SAEs were incompletely reported
in the studies. Regarding QoL, Carruthers et al. (36) reported a
significant decrease in PGA (p < 0.00001) with 23/30 patients
achieving a PGA score of 0.
Discussion
The presented information seems promising in terms of a
corticosteroid-sparing effect of RTX, however, no blinded RCTs
in IgG4-related disease exist to date.
Immune Thrombocytopenia
Five open-label and two double-blind RCTs met the inclusion
criteria of our systematic review (41–47). In total 644 patients
were treated with RTX or when assigned to the control group
either corticosteroids, placebo, vincristine or a RTX, CYC,
vincristine, prednisone (R-CVP) regime. Follow-up was between
6 months and 3 years.
Two of the three studies investigating the efficacy of RTX
vs. corticosteroids found significantly higher sustained response
rates in the RTX group (44, 46, 47). However, the third study
found no significant difference (46). In comparison to placebo,
RTX led to a reduction in treatment failure, a significantly
prolonged time to relapse, and higher platelet counts (41, 43).
There was no significant difference in response rates between
patients re-treated with RTX and those re-treated with R-
CVP (45).
Dai et al. (42) included 50 pediatric patients in their RCT
evaluating the efficacy of RTX compared to vincristine. They
found that response rates in the RTX group were significantly
higher and therefore concluded that standard dose (375 mg/m2)
RTX is an effective and preferred therapy for children with
immune thrombocytopenia, without SAEs.
Most of the studies stated AEs to be of mild or moderate
intensity. SAEs were reported by four of the seven studies with
one study reporting a significantly increased rate of SAEs. QoL
was evaluated in one study using the SF-36 showing no significant
changes (41).
Discussion
The use of RTX in adult and pediatric patients with ITP showed
efficacy while having an acceptable safety profile.
Inflammatory Myositis
One double-blind RCT was found investigating the use of
RTX in children and adults suffering from either poly- or
dermatomyositis (48). Study duration was 44 weeks. Two
hundred patients were randomized to either RTX early, receiving
RTX at weeks 0 and 1 and placebo at weeks 8 and 9,
or the RTX late arm with a reversed treatment regimen.
Concomitant use of corticosteroids and immunosuppressive
agents was allowed. Results showed no significant difference
in time to reach the improvement threshold. As study arms
received RTX, AEs were mostly from infusion reactions
or infections.
Discussion
Available information is derived from one double-blind RCT
showing no significant difference concerning the efficacy of RTX.
Juvenile Idiopathic Arthritis
Two studies were included, one open-label trial with 55
patients and one case series with three patients (49, 50).
All 58 patients suffered from severe active systemic juvenile
idiopathic arthritis with an inadequate response to standard
treatment. Primary endpoint of the open-label trial was an
American College of Rheumatology (ACR) pediatric 30 response
at week 24.
The case series by Narvaez et al. (49) demonstrated significant
clinical improvement in all three patients. Alexeeva et al. (50)
showed a significant improvement in the American College of
Rheumatology Pediatric 30 response rate with 98% of the patients
reaching it at week 24. Systemic manifestations were significantly
reduced by week 12. After 1 year of treatment, 75% of the patients
reached clinical remission.
An infusion reaction during the second infusion was the only
AE occurring in the case series. There were no SAEs and no
deaths reported. However, the open-label trial registered 101 AEs
with the most common AE being infusion reactions. There was
no information about SAEs and deaths.
QoL was assessed using the childhood health assessment
questionnaire (HAQ) score and showed a significant
improvement after 12 weeks.
Discussion
Currently available results seem very promising and support
further investigation in bigger randomized-controlled and
double-blind trials.
Membranous Nephropathy
Only one open-label RCT on the use of RTX in patients with
membranous nephropathy met the inclusion criteria and time
frame of our systematic review. In the included RCT, diagnosis
of membranous nephropathy had to be proven by biopsy and
patients had to have a non-response to non-immunosuppressive
antiproteinuric treatment (NIAT). Seventy five patients were
treated with either RTX in combination with NIAT or NIAT
alone over a period of 6 months (51).
There was no noteworthy difference concerning the
primary endpoint, i.e., remission after 6 months. Nonetheless,
significantly more patients achieved remission during the follow-
up period. There was no information about AEs. However,
five patients in the RTX group and four in the NIAT group
experienced a SAE.
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Discussion
The included trial led to contradictory results. A recent RCT
became available during the publication of this manuscript and,
thus, did not meet the time frame criterion of our systematic
review. This recent RCT showed that RTX was equivalent to
cyclosporine in inducing remission of proteinuria in patients
with membranous nephropathy and superior in maintaining
proteinuria remission up to 24 months (52).
Multiple Sclerosis
Three double-blind placebo-controlled RCTs totaling 570
patients fit our inclusion criteria (53–55). Study duration ranged
from 48 to 122 weeks. Each study was conducted in a different
form of multiple sclerosis (MS). Hauser et al. (53) included
patients with relapsing-remitting MS (RRMS) with at least one
relapse during the past year but no relapse within the last 30
days. Hawker et al. (54) investigated the efficacy of RTX in
patients with primary progressive MS (PPMS) without history
of relapses, and the RIVITALISE trial only included patients
with secondary progressive MS with no relapse during the last
year (55). The latter study was the only one using intrathecal
RTX. Only Hauser et al. and Hawker et al. had predefined
endpoints which were the total count of gadolinium-enhancing
lesions on T1-weighted MRI scans and time to confirmed disease
progression (53, 54).
One hundred and four patients with RRMS were treated
with either RTX or placebo. RTX treated patients experienced
a notable drop in the annualized relapse rate and MRI showed
a significant reduction in the total number of gadolinium-
enhancing lesions (53). Conversely, patients with PPMS failed
to show a significant difference in time to confirmed disease
progression between RTX and placebo (54). Likewise, RTX did
not show efficacy in patients with secondary progressive MS
with no relapse during the last year and, thus, the RIVITALISE
trial was terminated prematurely and results and AEs were not
analyzed (55).
98.6 and 13% of the patients with RRMS treated with RTX and
100 and 14.3% of the patients treated with placebo had at least one
AE or SAE, respectively. Patients with PPMS had a 99% incidence
of AEs in the RTX group and 100% in the placebo group. SAEs
occurred with a frequency of 13.6–16.4%. Two patients treated
with RTX and two treated with placebo died.
Discussion
Although the sample size was small, results in patients with
RRMS seemed very promising and support the initiation of
further studies using RTX. In patients with PPMS the outcomes
were less convincing. However, available data favors a RTX vs. a
placebo treatment. Thus, a treatment benefit cannot be ruled out.
Results in patients with secondary progressiveMS are not reliable
due to early termination.
Myasthenia Gravis
Nine case series and one uncontrolled open-label trial with its
follow-up were analyzed (56–66). In total 108 patients were
treated with RTX. Concomitant treatment varied widely. While
some patients had to discontinue immunosuppressive agents,
others were allowed to continue. None of the case series had
predefined endpoints. The change in manual muscle testing
score was the primary endpoint of the open-label trial and its
follow-up study.
The only study with a predefined endpoint achieved it
showing a significant improvement in the manual muscle
testing score as well as a significant reduction in the
need for plasma exchange, intravenous immunoglobulin, and
prednisone. These results were reflected also during the follow-
up trial. Concerning other studies, all of them reported
an improvement in disease symptoms. In addition, most
patients were able to taper corticosteroids, immunosuppressive
treatment, and cholinesterase inhibitors. However, patients
with anti-muscle-specific kinase antibodies tended to show
better responses than patients with anti-acetylcholine receptor
antibodies (57–64, 66).
Only three studies reported on AEs (56, 57, 61). QoL was
assessed in one trial using theMyasthenia Gravis-Specific Quality
of Life Score 15 but failed to demonstrate any significant
improvement (66).
Discussion
Although only case series and uncontrolled open-label trials
are available, current data are very promising, showing an
improvement in disease symptoms and the possibility to taper
corticosteroids as well as cholinesterase inhibitors. Further trials
investigating the use of RTX in patients with myasthenia gravis
are thus warranted.
Nephrotic Syndrome
Six clinical trials with idiopathic nephrotic syndrome matching
our inclusion criteria were identified, including one follow-
up trial (67) and five RCTs (68–72). All but one RCT was
conducted open-label (68). Two hundred and eighty three
pediatric patients participated in either of the five RCTs. A
diagnosis of idiopathic nephrotic syndrome was required in all
studies as well as an eGFR of at least 60 ml/min. All patients
received concomitant prednisone, which was tapered during
the study period. Concomitant use of angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers
was allowed.
Only one of the three trials assessing proteinuria as primary
endpoint found a significantly better result in RTX-treated
patients (67). However, the reported median relapse-free period
was significantly longer in RTX patients with a significantly
reduced relapse rate (67–69, 71, 72). Additionally, required
corticosteroid doses were significantly lower with concomitant
RTX. Reliable information about the incidence of AEs, SAEs,
and deaths were provided by two studies showing a comparable
incidence between RTX, tacrolimus and placebo (68, 72). None
of the studies assessed QoL.
Discussion
Although RTX treatment did not affect proteinuria, such
treatment significantly reduced the relapse rate and the
required dose of corticosteroids. Information about safety
was lacking.
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Neuromyelitis Optica
We found one open-label RCT in patients with neuromyelitis
optica (73). It included 86 patients with a neuromyelitis optica
spectrum disorder and an Expanded Disability Status Scale of
0–7 in the previous 12 months. The control group received
AZA in combination with prednisolone which was tapered
over time.
The primary endpoint was the annual relapse rate after
12 months, which was achieved. Furthermore, RTX led to a
significant decrease in the Expanded Disability Status Scale
when compared to AZA. The incidence of AEs was not
significantly different.
Discussion
In the only available RCT, RTX proved its superiority over
AZA in the treatment of neuromyelitis optica. However, further
blinded studies are needed to confirm this.
Pemphigus
Two RCTs matched our inclusion criteria (74, 75). One of them
was observer blinded, the other was an open-label trial. One
hundred and twelve patients with either pemphigus vulgaris or
pemphigus foliaceus were treated with RTX or prednisone.
Kanwar et al. (74) assessed the efficacy of different RTX
dosing regimens and concluded that there was no difference
in the time taken to achieve any of the primary endpoints
(partial and complete remission). However, relapse seemed
to be more common in patients who received low-dose
RTX (74). Joly et al. (75) demonstrated that significantly
more patients treated with a combination of RTX and a
corticosteroid achieved remission off corticosteroids after 24
months as compared to patients treated with corticosteroids
solely. Furthermore, these patients achieved remission
significantly faster and time of remission off corticosteroids was
significantly longer.
The dermatology life quality index and skindex scores were
significantly better in patients treated with RTX, SAEs, and AEs
were not significantly different between the groups.
Discussion
RTX proved its steroid-sparing effect and furthermore led to
a significantly longer remission duration off corticosteroids.
The FDA and EMA approved its use for moderate-to-severe
pemphigus vulgaris in adult patients.
Rheumatoid Arthritis
Nineteen trials matching our inclusion criteria were identified
(76–94). All but five studies were double-blind. RTX was
compared to placebo,MTX, leflunomide, TNF inhibitors, or itself
at different dosages. Major inclusion criteria was a diagnosis of
rheumatoid arthritis (RA) usually according to the ACR criteria.
Except for one trial, patients needed to suffer from active disease.
The most frequently stated exclusion criteria were a concomitant
autoimmune disease other than RA and a systemic involvement
of RA.
Ten trials including one follow-up trial investigated the
use of RTX in comparison to placebo or disease-modifying
antirheumatic drugs (DMARDs) in patients with active RA
despite the use of MTX (77–79, 83–86, 88, 92, 94). In most
of the studies, a combination therapy of RTX and MTX was
superior to placebo and MTX in terms of efficacy. In addition,
Edwards et al. (77) reported significantly better results when
RTX plus MTX or RTX plus CYC was used in comparison
to MTX monotherapy. However, RTX monotherapy was not
significantly better thanMTXmonotherapy when analyzing ACR
response rates. Owczarczyk et al. (83) did not predefine an
endpoint, and therefore failed to show significant differences
between RTX and MTX monotherapy concerning the disease
activity score (DAS) 28 and EULAR (European League Against
Rheumatism) response. Peterfy et al. (84) investigated the change
in the RA magnetic resonance imaging erosion score and found
a significant reduction in radiographic progression at week 24 in
RTX-treated patients irrespective of the dosage used as compared
to placebo.
The REFLEX trial was conducted in patients with active RA
despite the use of one or more TNF inhibitors and investigated
the ACR20 response rate at 24 weeks as its primary endpoint (76).
It also found RTX in combination with MTX to be significantly
superior to MTX monotherapy. A substudy of this trial observed
superiority of RTX combination therapy in the Genant-modified
Sharp score at week 56 (90). Similar results were reported by
the SUNRISE trial assessing the ACR20 response rate at week
48 (82).
SMART, a further trial conducted in TNF inhibitor-resistant
patients tested a retreatment after 24 weeks with either one or
two doses of 1,000mg RTX and found no statistically significant
difference between these dosing regimens (81).
The DANCER, SERENE, and MIRROR trials aimed to
assess the effectiveness of different doses of RTX (500mg vs.
1,000mg) in combination with MTX. In these trials, RTX-
treated patients achieved significantly higher ACR20 response
rates as compared to placebo, independent of the dose
administered (78, 79, 92). Furthermore, there was no significant
difference between the two dosing regimens as reported by
the DANCER and MIRROR trials concerning the ACR50/70
response rates.
Vital et al. (94) compared an induction therapy of RTX given
on weeks 0, 2, and 4, to an induction therapy with only two doses
given on weeks 0 and 2. They found a significantly greater B cell
depletion paralleled by significantly better EULAR and ACR20
response rates at 40 and 52 weeks in patients with an induction
treatment of three doses. Furthermore, they demonstrated that
immunoglobulin titers remained stable in both arms, and AEs
were balanced.
When assessing RTX plus a TNF inhibitor and MTX,
Greenwald et al. (80) concluded that the preliminary safety profile
of RTX plus a TNF inhibitor and MTX was consistent with the
safety profile of RTX plus MTX without a TNF inhibitor, with
no new safety signals observed. However, in comparison to the
control group, receiving placebo plus MTX and a TNF inhibitor,
AEs and SAEs were numerically more frequent in the RTX group,
and there was no clear evidence of an efficacy advantage in
patients receiving RTX in combination with a TNF inhibitor
and MTX.
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Some investigations have turned their attention to trying
to find valid alternatives to RTX. Wijesinghe et al. (86)
assessed ACR20/50/70 response rates and found no significant
difference between patients treated with RTX and those treated
with leflunomide.
A recent trial published compared abatacept, an alternative
TNF inhibitor and RTX in patients with an inadequate
response to TNF inhibitors and MTX, and found no significant
difference concerning DAS28 response at 24 weeks, which
was the primary endpoint (87). Yet, abatacept tended to be
less effective when analyzing ACR20, EULAR response, the
clinical disease activity index and simple disease activity index.
However, there were too few patients included to draw a
clear conclusion.
Since study duration, premedication, dosing regimen, and
control group treatment varied markedly, a comparison of
different incidence rates of AEs is difficult. Five trials did not
report about AEs at all (83, 86, 88, 90, 91). None of the trials
analyzing safety reported a significantly increased rate of AEs,
SAEs, or deaths.
Various trials assessed QoL. Seven reported a
significant improvement in HAQ disability index (76–
79, 89, 90, 92, 93), four in functional assessment of chronic
illness therapy—fatigue scale (76, 78, 79, 92), and three in
SF-36 (76, 78, 92). The SUNRISE, ORBIT, SMART, and
SWITCH trials as well as the study of Wijesinghe et al.
(86) found no significant improvement in QoL measures
(82, 85, 87).
Discussion
The use of RTX in patients with RA was approved by the
FDA and the EMA. However, its use is restricted to patients
suffering from severe (EMA) or moderate-to-severe (FDA) active
disease with an inadequate response to previous treatment
options of DMARDs including at least one TNF inhibitor.
RTX has to be administered in combination with MTX and
an appropriate premedication to prevent infusion reactions.
Newer studies aim to prove the non-inferiority of biosimilars
to RTX.
Sjögren’s Syndrome
Four double-blind RCTs and one substudy were
identified (95–99). All 298 included patients had a
diagnosis of primary Sjögren’s syndrome according to
the American-European Consensus Group Criteria for
primary Sjögren’s syndrome. All studies compared RTX
to placebo.
Three out of five studies failed to achieve their primary
endpoint (95, 96, 98). The study of Dass et al. (95) could not
show a superiority of RTX concerning a 20% improvement in a
visual analog scale to evaluate fatigue severity (VAS-F). Neither
did the study of Bowman et al. (98) assessing a 30% reduction in
VAS-F or oral dryness. The TEARS trial did not meet its primary
endpoint either (96). However, significantlymore patients treated
with RTX reached the primary endpoint in the study of Meijer
et al. (97) with a significant improvement in the stimulated whole
saliva flow rate.
Three trials evaluated the influence of RTX treatment
on QoL using the SF-36 score. While two studies found a
significant improvement (95, 97), the third failed to show any
difference (98).
The TEARS trial and the study of Bowman et al. were the only
studies providing reliable data on safety events. Despite the use
of acetaminophen and corticosteroid as premedication, infusion
reactions occurred significantly more often in the RTX group
(96). Other AEs were comparable.
Discussion
Although three out of five trials did not meet their primary
endpoint, RTX may be a possible treatment option for patients
suffering from primary Sjögren syndrome. Thus, further trials
with an appropriate dosing schedule including more patients are
needed to draw a clear conclusion.
Spondyloarthropathy
Two open-label clinical trials as well as one follow-up trial were
included for analysis (100–102). All 29 patients were treated
with RTX without a matching control group. One study was
conducted in patients with active ankylosing spondylitis despite
the use of at least two NSAIDs, the other comprised patients with
active psoriatic arthritis despite the use of MTX.
Forty percentage of all patients with ankylosing spondylitis
achieved an Assessment of SpondyloArthritis International
Society 20 response at week 24, which was the primary
endpoint. Remarkably, TNF inhibitor-naïve patients had
better treatment outcomes concerning Assessment of
SpondyloArthritis International Society 20/40 response, partial
remission, and Bath Ankylosing Spondylitis Disease Activity
Index 20/50.
Primary endpoint in psoriatic arthritis patients was a
psoriatic arthritis response criteria improvement by 30% of
tender and swollen joint count or if only one fulfilled,
an additional 30% improvement of patient or evaluator
global assessment. It was met by 56% of all patients.
However, dactylitis remained stable, while enthesitis symptoms
significantly improved.
Safety reporting was incomplete with only two studies
reporting AEs (100, 101). QoL was only analyzed in patients with
psoriatic arthritis and showed a significant improvement.
Discussion
Results in ankylosing spondylitis and psoriatic arthritis
patients were promising with improvements in Assessment
of SpondyloArthritis International Society response, psoriatic
arthritis response criteria and DAS28. Nevertheless, both
trials were conducted without a control group making an
interpretation of RTX’s efficacy difficult. Furthermore, safety
reporting was poor.
Systemic Lupus Erythematosus
We found four RCTs matching our inclusion criteria (103–
106), with three of them conducted in a double-blind
manner. Five hundred and four patients with a diagnosis of
SLE according to the ACR criteria were randomized. Three
studies were conducted in patients with concomitant lupus
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TABLE 2 | Downs and black assessment.
Study Total
Scores
Risk of
bias
Stone et al. (6) (RAVE) 20 Medium
Specks et al. (7) (extension of RAVE) 18 Medium
Miloslavsky et al. (8) (open-label extension
of RAVE)
13 High
Jones et al. (9) (RITUXVAS) 20 Medium
Jones et al. (10) (extension of RITUXVAS) 17 Medium
Berden et al. (5) (substudy of RITUXVAS) 15 Medium
De Menthon et al. (11) 14 High
Guillevin et al. (12) (MAINRITSAN) 18 Medium
Charles et al. (13) (MAINRITSAN2) 20 Medium
Erkan et al. (14) (RITAPS) 18 Medium
Birgens et al. (15) 22 Low
Michel et al. (16) (RAIHA) 23 Low
Burak et al. (17) 14 High
Davatchi et al. (18) 16 Medium
Hall et al. (19) 13 High
Levi et al. (4) 11 High
Busse et al. (3) 10 High
Marcelin et al. (24) 18 Medium
Ide et al. (23) 17 Medium
Bower et al. (21) 19 Medium
Gerard et al. (22) 18 Medium
Powles et al. (26) 12 High
Bestawros et al. (20) 12 High
Peker et al. (25) 4 High
Uldrick et al. (27) 17 Medium
Dammacco et al. (28) 26 Low
De Vita et al. (29) 21 Low
Quartuccio et al. (31) (Follow-up of De Vita
et al.)
16 Medium
Sneller et al. (30) 28 Low
Oddis et al. (48) (RIM trial) 25 Low
Ravani et al. (70) 25 Low
Ravani et al. (67) 17 Medium
Magnasco et al. (69) 24 Low
Iijima et al. (68) 27 Low
Ravani et al. (71) 23 Low
Basu et al. (72) (RITURNS) 26 Low
Dahan et al. (51) 23 Low
Lafayette et al. (35) 23 Low
Shah et al. (32) 5 High
Salvi et al. (33) 21 Low
Stan et al. (34) 24 Low
Khosroshahi et al. (37) 8 High
Khosroshahi et al. (38) 16 Medium
Carruthers et al. (36) 17 Medium
Yamamoto et al. (39) 8 High
Quattrocchio et al. (40) 12 High
Hasan et al. (45) (only considering Part 2) 5 High
(Continued)
TABLE 2 | Continued
Study Total
Scores
Risk of
bias
Zaja et al. (47) 20 Medium
Li et al. (46) 23 Low
Arnold et al. (41) 27 Low
Gudbrandsdottir et al. (44) 21 Low
Dai et al. (42) 11 High
Ghanima et al. (43) (RITP trial) 25 Low
Narvaez et al. (49) 6 High
Alexeeva et al. (50) 16 Medium
Merrill et al. (103) (EXPLORER trial) 27 Low
Rovin et al. (104) (LUNAR trial) 23 Low
Zhang et al. (105) 10 High
Andrade-Ortega et al. (106) 19 Medium
Hauser et al. (53) 21 Low
Hawker et al. (54) 27 Low
Komori et al. (55) (RIVITALISE trial) 21 Low
Illa et al. (58) 14 High
Lebrun et al. (60) 12 High
Nelson et al. (62) 5 High
Stieglbauer et al. (63) 7 High
Lindberg et al. (61) 9 High
Diaz-Manera et al. (57) 16 Medium
Sun et al. (64) 14 High
Anderson et al. (56) 16 Medium
Beecher et al. (65) (extension trial of
Anderson et al.)
13 High
Lebrun et al. (59) 17 Medium
Jing et al. (66) 19 Medium
Nikoo et al. (73) 23 Low
Joly et al. (75) (Ritux 3) 25 Low
Song et al. (101) 17 Medium
Song et al. (102) [Follow-up trial of Song
et al. (101)]
15 Medium
Jimenez-Boj et al. (100) 15 Medium
Daoussis et al. (107) 21 Low
Leiper et al. (108) 25 Low
Dass et al. (95) 22 Low
Meijer et al. (97) 27 Low
Devauchelle-Pensec et al. (96) (TEARS
trial)
26 Low
Bowman et al. (98) (TRACTISS) 26 Low
Fisher et al. (99) (substudy of TRACTISS) 25 Low
Edwards et al. (77) 26 Low
Strand et al. (88) [2 year follow-up of
Edwards et al. (77)]
22 Low
Cohen et al. (76) (REFLEX trial) 26 Low
Keystone et al. (90) (substudy of the
REFLEX trial)
26 Low
Emery et al. (79) (DANCER trial) 25 Low
Owczarczyk et al. (83) 12 High
Emery et al. (78) (SERENE trial) 24 Low
Mease et al. (82) (SUNRISE trial) 26 Low
(Continued)
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TABLE 2 | Continued
Study Total
Scores
Risk of
bias
Greenwald et al. (80) (TAME trial) 22 Low
Tak et al. (93) (IMAGE trial) 25 Low
Tak et al. (89) (Extension of the IMAGE trial) 26 Low
Mariette et al. (81) (SMART trial) 22 Low
Vital et al. (94) 23 Low
Peterfy et al. (84) (RA-SCORE trial) 25 Low
Porter et al. (85) (ORBIT trial) 24 Low
Wijesinghe et al. (86) 23 Low
Brown et al. (87) (SWITCH RCT) 22 Low
Rubbert-Roth et al. (92) 28 Low
Bingham et al. (91) 14 High
Kanwar et al. (74) 20 Medium
nephritis. Patients were randomized to either RTX, CYC,
or placebo.
Zhang et al. (105) compared RTX in combination with CYC
to CYC alone and found a significantly higher response rate
in terms of the amount of proteinuria during 1 day and a
higher serum albumin concentration in patients receiving a
combination of RTX and CYC. The LUNAR trial, comparing
the efficacy of RTX to placebo in lupus nephritis patients, found
no significant differences concerning the primary endpoints
(104). The EXPLORER study using RTX in SLE patients found
also no indication for a superiority of RTX above placebo
concerning clinical response rate. However, a subanalysis found
significantly better results in African American and Hispanic SLE
patients (103).
The LUNAR trial was the only study reporting AE frequency
with 98.6% of RTX-treated patients and 95.8% of placebo-
treated patients experiencing at least one AE (104). SAEs and
deaths were reported by three of the studies and showed similar
incidence rates of RTX and placebo (103, 104). The two studies
investigating QoL using the SF-36 score found no significant
improvement (103, 104).
Discussion
Efficacy of RTX was assessed using a definition of complete
response, major clinical response, and renal response. Only one
trial showed a superiority of RTX over a conventional treatment
(105). However, two substudies came to the conclusion that
African American and Hispanic SLE patients may profit from
a treatment. Thus, further studies investigating this supposition
are necessary.
Systemic Sclerosis
One open-label trial with blinded outcome assessors including 14
patients met our inclusion criteria (107). A diagnosis of diffuse
systemic sclerosis according to the ACR criteria was the main
inclusion criteria. Furthermore, patients needed to be anti-Scl-
70 autoantibody positive and had to have an interstitial lung
disease. The trial compared efficacy of RTX vs. standard-of-
care treatment.
Patients treated with RTX showed a significant improvement
in forced vital capacity, diffusing capacity of the lungs for carbon
monoxide (DLCO) and modified Rodnan skin score after 1 year,
while patients receiving standard of care showed a deterioration
in forced vital capacity and DLCO.
Safety outcomes were poorly reported. The assessment of QoL
showed a significant improvement after 1 year of RTX treatment
using the HAQ score.
Discussion
The only available trial showed promising results concerning
lung function and skin thickening. Nevertheless, the trial
was rather small and unblinded, and safety outcomes were
poorly reported.
Ulcerative Colitis
One double-blind RCT conducted over a 24 week time period
was eligible for our review (108). Twenty four patients fulfilled
the inclusion criteria of moderately active ulcerative colitis with
inadequate response to corticosteroid treatment. The control
group received matching placebo.
The primary endpoint, remission after 4 weeks, was not met.
Safety was comparable between RTX and placebo. There was no
difference concerning the QoL as measured by the inflammatory
bowel disease questionnaire.
Discussion
RTX treatment in patients with ulcerative colitis did not meet any
of the predefined endpoints. Safety was comparable between RTX
and placebo.
Risk of Bias
Results of the risk of bias and quality assessment of individual
studies are available in Table 2. Due to the heterogeneous
results reporting the primary and secondary outcomes of the
trials in individual diseases as well as the high possibility of
publication bias we did not carry out a risk of bias assessment
across studies.
DISCUSSION
Summary of Main Findings
As summarized in Table 3, RTX has been approved by the FDA
and EMA for the treatment of ANCA-associated vasculitis, RA
and pemphigus vulgaris. RCTs have demonstrated the efficacy
and safety of RTX in autoimmune hemolytic anemia, Behçet’s
disease, cryoglobulinemia, ITP, MS, neuromyelitis optica, and
systemic sclerosis. Conversely, results with the use of RTX
in patients with inflammatory myositis, primary Sjögren’s
syndrome, SLE, Grave’s disease, and ulcerative colitis were
rather negative.
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TABLE 3 | Summary of the results.
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PPMS RRMS
Level I
Level IIa
Level IIb
Level IIIa
Level IIIb
Level IV
Too little
information
Legend
Level I Approved by FDA/EMA
Level IIa Multicentric double-blind RCTs proving a significant superiority over standard-of-care treatment
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*Acquired angioedema with C1-inhibitor deficiency.
Clinical studies showed promising results in patients with
bullous pemphigoid, C1-INH-AAE, Castleman’s disease,
idiopathic nephrotic syndrome, Goodpasture’s syndrome, IgG4-
related disease, juvenile idiopathic arthritis, myasthenia gravis,
and spondyloarthropathy. Available results for the treatment of
IgA nephropathy showed no effects.
Notably, a recent RCT in patients with membranous
nephropathy was released during the publication of this
manuscript and, thus, could not be included in this systematic
review. This RCT showed similar or superior efficacy of RTX
in terms of inducing and maintaining reduced proteinuria in
patients with membranous nephropathy (52). A more detailed
overview of the safety of RTX in individual diseases is given
in Table 4.
Limitations
To our knowledge this is the first synthesis of data on RTX
in immune-mediated diseases. We have used standardized
systematic overview techniques, which have helped to minimize
the risk of bias. Furthermore, we assessed the quality and
bias of each study using the Downs and Black checklist
(see Table S4).
However, our systematic review has some limitations.
Firstly, we included studies with different patient
ages, concomitant treatments, premedications, control
groups, and study durations making a direct comparison
difficult. Secondly, published studies used different
primary endpoints, inclusion criteria and dosing
regimens making a direct comparison in a meta-analysis
very difficult.
Conclusions
Since RTX first came on the market over 20 years ago, it
has offered a new dimension of targeted treatment in many
immune-mediated diseases that were previously not or
only insufficiently amenable to treatment. A systematic and
comprehensive document establishing the safety and efficacy of
RTX in different immune-mediated diseases to our knowledge
has not yet been published, making our work novel in this
field. We narrate the potential use for RTX, demonstrating
its safety and efficacy that has led to regulatory approval in
certain pathologies and its potential as a valid alternative to
others. However, where the safety and efficacy of RTX cannot
be established, due to the lack of unbiased trials, we call upon
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TABLE 4 | Adverse events.
Organ systems
affected
Adverse event(s) References
Systemic (a) Immediate-type adverse reactions Cytokine release syndrome, infusion reactions (often present during first
RTX infusion and decrease with subsequent infusions)
(9, 12, 14, 18, 22, 27, 30, 33,
35, 38, 41, 44–46, 48–50, 52–
54, 56, 57, 67–74, 76, 78–
85, 87, 89, 91–93, 95–98, 101,
103, 104, 108)
(b) Late-type immune mediated
adverse reactions
Serum sickness (95, 97, 101, 103)
(c) Infection Most commonly affecting ears, nose and upper respiratory tract; rarely
prostatitis, urinary infection, septicaemia, colitis, pyelonephritis and others
(6–8, 12–14, 16, 18, 22, 29–
31, 35, 36, 40, 41, 43, 44, 48,
50, 52, 54, 67, 72, 74–87, 89,
92–94, 97, 98, 100, 107, 108)
(d) Malignancy Worsening or reactivation of Kaposi sarcoma (in Castleman’s disease)
Single cases of other malignancies were reported in several studies in study
groups involving or not involving RTX treatment, however a connection to
RTX treatment was never obvious. For this matter we refer to two systematic
reviews, one finding no association of malignancy with RTX (109), the other
reporting a slightly increased risk of cutaneous melanoma (110).
(20–22, 24)
Cardiovascular Venous thrombotic events, pulmonary embolism, cardiovascular such as: myocardial infarction, heart failure, supraventricular tachycardia, dysrhythmia,
hypotension, cerebral infarction, angina, coronary artery disease
(6, 7, 9, 12–14, 46–48, 51–53,
77–80, 86, 91, 93)
Gastrointestinal and
hepatic
Gastrointestinal symptoms: nausea, reflux disease, stomatitis, anorexia, gastrointestinal bleeding, abdominal pain, diarrhea, appendicitis, increased
transaminases, gastritis, pharyngolaryngeal pain, acute liver failure (single case in hepatitis C-related cryoglobulinemia)
Reactivation of hepatitis B***
(14, 27, 29, 34, 35, 38, 43, 48,
51, 52, 69, 71, 72, 74, 78, 81,
85, 87, 95, 98)
(111)
Hematologic events Cytopenias, including anemia, thrombocytopenia, leukopenia, neutropenia, hypogammaglobulinemia [27%; (112)], and agranulocytosis (6, 7, 9, 12, 16, 22, 27, 30, 31,
44, 48, 50, 61, 67, 68, 72, 84,
85, 87, 103, 104)
Musculoskeletal Myalgias, arthralgias, arthritis, rarely bone fractures (4, 14, 34, 41, 52, 67, 70, 71,
75, 84, 85, 87, 91, 98)
Nervous system
(including eyes)
Neuropsychiatric problems, neurologic symptoms such as headache and dizziness, optic neuropathy in Grave’s disease, fatigue (14, 34, 36, 41, 52, 79, 84, 85)
Renal Renal failure (described in ANCA-associated vasculitis) (9)
Upper and lower
airways
Hemorrhagic alveolitis (single case), pneumonia, bronchospasm, mild dyspnea, throat irritation (29, 47, 54, 61, 67, 69, 70, 72,
77, 82, 85, 96, 100, 108)
Skin Rash, itching, pruritus, acneiform eruptions, erythema, purpura (14, 34, 42, 43, 48, 53, 54, 67,
69–71, 74, 77, 84, 85, 87)
List of adverse side events per organ system.
***Although these adverse events were not significant in our systematic review, narrative reviews have highlighted these adverse events.
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the scientific community to undertake robust RCTs to assess
its potential.
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